Peer-reviewed veterinary case report
Splenic lymphoma in 5 dogs treated with surgery and chemo
By Stefanello, D et al.·Published in Journal of veterinary internal medicine·2011·Department of Veterinary Clinical Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Splenic marginal zone lymphoma in 5 dogs (2001-2008).
- Species:
- dog
Plain-English summary
A 5-year-old dog with splenic marginal zone lymphoma (a type of cancer affecting the spleen) was treated after showing symptoms like a ruptured spleen. Four dogs underwent surgery to remove the spleen and received chemotherapy with doxorubicin, while one dog had surgery alone. Most of the dogs that received both treatments lived for several years without lymphoma-related issues, but one dog that didn't get chemotherapy had a tumor return after about six months. The dog that received both surgery and chemotherapy is still in complete remission after over a year.
People also search for: dog splenic lymphoma treatment · dog spleen surgery recovery · doxorubicin for dog cancer
Abstract
BACKGROUND: Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can progress slowly. OBJECTIVES: To describe clinical features, treatment, and outcome of dogs with splenic MZL. ANIMALS: Five dogs with naturally occurring MZL. METHODS: Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histopathological, and immunophenotypic features. RESULTS: All dogs had stage IV disease; among them, 2 were symptomatic (substage "b") because of splenic rupture. Four dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor after 180 days. CONCLUSIONS AND CLINICAL IMPORTANCE: Splenic MZL appears indolent and can benefit from splenectomy, with or without systemic chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21092007/